Dec 11 (Reuters) - Impax Group PLC:
* Provides update on meeting with FDA to review Phase III trial results for
IPX056
* Impax Laboratories Inc says was requested to collect additional
longer-term
controlled clinical data on safety and efficacy
* Impax Laboratories says also evaluating potential need to conduct a
pediatric
study under the Pediatric Research Equity Act
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223
8780))
(For more news, please click here)
COPYRIGHT
Copyright Thomson Reuters 2008. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including
by framing or similar means, is expressly prohibited without the prior written
consent of Thomson Reuters.
|